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INTRODUCTION
The goal of this project is to identify novel therapeutic strategies aimed at counteracting or reversing drug resistance in breast cancer. Chemotherapeutic drug resistance, or failure to initiate apoptosis as a response to a chemotherapeutic drug, may result, in part, from a shift in the regulation of cellular mechanisms away from apoptosis to a more survivaloriented pathway. A diminished susceptibility to apoptosis may be mediated by the differential expression certain key proteins, which serve as molecular determinants for the cancer cell's capacity to survive many environmental stresses, including chemotherapeutic drug treatments. Two proteins that have been implicated as antiapoptotic are protein kinase C and phosphatidylinositol 3-kinase. Although differential expression of these kinases have been linked to anti-apoptotic signaling mechanisms, the molecular details of upstream and downstream events are not well understood, and therefore elucidation of their mechanisms of action may represent a potential therapeutic target for breast cancer. Using an isogenic model system of estrogen receptor positive, apoptosis-sensitive and apoptosis-resistant MCF-7 breast cancer cell variants, this proposal aims to define the role of phosphatidylinositol 3-kinase and specific protein kinase C isoforms in cellular apoptotic signaling pathways. It is expected that a detailed understanding of the role of these two kinases in breast cancer cell anti-apoptotic signaling pathways will provide opportunities for novel pharmacological interventions in in vivo model systems. The goal of this study is to investigate the role of PI3K and PKC in chemoresistance in breast cancer. I began my studies using a previously published model system using isogenic MCF-7 cell variants, (MCF-7 N (apoptosis-sensitive) and MCF-7 M (apoptosis-resistant), which exhibited differential sensitivity to TNF-cc and other chemotherapeutic drugs. While the MCF-7 M variant was less sensitive to TNF-a than the N variant, it still was partial susceptible to the cytotoxic effects of TNF-cc. In order to have a more complete model of resistance, and to more effectively investigate the role of PI3K and PKC in MCF-7 breast cancer cell survival, this lab has developed an MCF-7 variant (MCF-7 TN) which exhibits nearly complete resistance to TNF-a, from the MCF-7 N (apoptosis-sensitive) variant. The resistance of this variant was confirmed using trypan blue viability, and long-term, clonogenic assays (Appendix, Figure One) . I have used immunoblotting in this MCF-7 model system to investigate which PKC isoforms have are altered between the MCF-7 N and MCF-7 TN variants. I have implicated PKC-cc and PKC-8 as potential determinants in MCF-7 cell variant resistance and survival, as these studies revealed an upregulation in the expression and phosphorylation of PKC-cc, with downregulation of PKC-8, with no detectable change in PKC-£ (Appendix, Figure Two) . While our laboratory has previously implicated PI3K-Akt as a survival factor in MCF-7 cell variants, I did not detect any significant changes in expression or phosphorylation of Akt in the N vs. TN variant. However, Akt activity assays have not yet been performed.
I have obtained genetic constructs for green fluorescent protein (GFP)-tagged PKC isoforms cc, ß, 8, e,y,r\, 0, and £, and have been able to transfect and detect the cc, ß, Y, t\, 0, and 4 constructs with good efficiency (Appendix, Figure Three) . However, I have had difficulty with constructs obtained for GFP-PKC 8 and e, and have not been able to detect these constructs with fluorescent microscopy. I am currently working on either obtaining new constructs for these isoforms. In addition, I have obtained and produced constructs for constitutive active (CA) and dominant negative (DN) PKC a, ß, 8, £, 0, and £, and am in the process of optimizing the use of these constructs. Last, I am using luciferase reporter gene assays to characterize the changes in NF-KB transcriptional activity in the MCF-7 TN variant versus the MCF-7 N variant. This laboratory has previously shown that the PI3K-Akt-NF-KB pathway is an important survival pathway in MCF-7 cells, Consistent with this, luciferase reporter gene assays have shown that the NF-KB pathway is dramatically up-regulated in the TN variant as compared to the N variant in response to TNF-cc treatment (Appendix, Figure Four) . Binding of TNF-a to its cell surface receptor can activate both survival and apoptotic responses, depending on the cell, many of which are dependent on activation of NF-KB. That NF-KB transactivation is increased to such a degree in the TNF-oc-resistant MCF-7 TN variant suggests that, in these cells, NF-KB is play an important role in TNF-a resistance.
KEY ACCOMPLISHMENTS
• 
CONCLUSIONS
The development of resistance to standard chemotherapeutic protocols is a major obstacle to successful treatment of almost a type of cancer. A complete and thorough understanding of how resistance develops in breast cancer cells is needed to more effectively treat this disease. Our MCF-7 breast cancer model system will be useful in determining how two known survival pathways affect one another in determining chemoresistance. 
